MSQC20

SILu^™Lite SigmaMAb Bevacizumab Monoclonal Antibody

recombinant, expressed in CHO cells

• Synonym(e): Mass spectrometry standard, Bevacizumab
• NACRES: NA.41
• UNSPSC Code: 12352203
• Clone: -
• Species reactivity: -
• Application: —
• Citations: -

Eigenschaften

• recombinant: expressed in CHO cells
• assay: ≥90% (SDS-PAGE)
• form: solid
• suitability: suitable for mass spectrometry
• shipped in: wet ice
• storage temp.: −20°C

Beschreibung

General description

SigmaMAb Bevacizumab (MSQC20) was designed to be a standard for the analysis of Bevacizumab monoclonal antibodies using mass spectrometry. An isotopically labeled version is available as SILu^™Mab Bevacizumab (MSQC21).

SigmaMAb Bevacizumab is for R&D use only. Not for drug, household, or other uses.

Application

SILu^™ Lite SigmaMAb Bevacizumab Monoclonal Antibody has been used as a proangiogenic factor to study its role in the angiogenesis process by Raman spectroscopy.

Biochem/physiol Actions

Bevacizumab serves as an antitumor agent. Studies show that chemotherapy using bevacizumab improves the condition of metastatic colorectal cancer and renal cell cancer patients.

Other Notes

SigmaMab Bevacizumab Heavy Chain:
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

SigmaMab Bevacizumab Light Chain:
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Legal Information

SILu is a trademark of Sigma-Aldrich Co. LLC

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3